cas 1131-01-7|| where to buy 2-chloro-N-(2,6-dimethylphenyl)acetamide

Nom du produit:2-chloro-N-(2,6-dimethylphenyl)acetamide

IUPAC Name:2-chloro-N-(2,6-dimethylphenyl)acetamide

Unité d'emballage	Stock disponible	Prix($)
CM114010-100g	in stock	ƻɅ
CM114010-500g	in stock	ŴȷɅ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1131-01-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1131-01-7; Formule moléculaire:C10H12ClNO; Point de fusion:-; Code SMILES:O=C(NC1=C(C)C=CC=C1C)CCl; Densité:

: Numéro de catalogue:CM114010; Poids moléculaire:197.66; Point d'ébullition:; N° Mdl:MFCD00000926; Stockage:

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Taplucainium chloride; Nocion Therapeutics presents data on preclinical and clinical development of Taplucainium, a novel, charged sodium channel blocker, as a potential treatment for chronic cough at the 13th London International Cough Symposium.
Taplucainium is a proprietary molecule in the novel class of charged sodium channel blockers that allows for specific silencing of activated/inflamed nociceptors while having minimal local off-target effects or systemic exposure. Unlike other investigative cough therapies, such as P2X3-antagonists, TRPA1-antagonists and TRPM8-agonists, which target a specific large pore channel, taplucainium works downstream by selectively targeting the sodium channels in activated nociceptors which are the target of these large pore channels.